Rutland Cedric J, Iweala Onyinye I, Anders Kyle, Ko Jinnie, Mital Parul, Gupta Sachin, Mohan Arjun
Rutland Medical Group, Newport Beach, CA, USA.
Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA.
J Asthma Allergy. 2023 Jun 24;16:661-665. doi: 10.2147/JAA.S412762. eCollection 2023.
Acute and chronic cough are common symptoms in patients with severe allergic asthma. Although asthma-related cough can be controlled by asthma-specific medications, both prescription and over-the-counter antitussives are often also necessary. The anti-immunoglobulin E monoclonal antibody omalizumab is an effective treatment for patients with moderate-to-severe asthma, but little is known about subsequent antitussive use patterns. This post hoc analysis examined data from the Phase 3 EXTRA study that included patients aged 12-75 years with inadequately controlled moderate-to-severe asthma. Baseline antitussive use was low overall (16/427, 3.7% for omalizumab and 18/421, 4.3% for placebo). Among patients with no baseline antitussive use (n = 411 omalizumab, n = 403 placebo), most patients (88.3% omalizumab, 83.4% placebo) reported not using antitussives during the 48-week treatment period. The percentage of patients using 1 antitussive was lower for patients treated with omalizumab than placebo (7.1% vs 13.2%), although the adjusted rate of antitussive use during the treatment period was similar for omalizumab and placebo (0.22 and 0.25). Non-narcotics were used more often than narcotics. In conclusion, this analysis found low use of antitussives in patients with severe asthma and suggests that omalizumab may have the potential to decrease antitussive use.
急性和慢性咳嗽是重度过敏性哮喘患者的常见症状。虽然与哮喘相关的咳嗽可以通过哮喘专用药物得到控制，但通常也需要使用处方药和非处方药止咳药。抗免疫球蛋白E单克隆抗体奥马珠单抗是治疗中重度哮喘患者的有效药物，但对于后续止咳药的使用模式知之甚少。这项事后分析检查了3期EXTRA研究的数据，该研究纳入了12至75岁、中重度哮喘控制不佳的患者。总体而言，基线时止咳药的使用率较低（奥马珠单抗组为16/427，3.7%；安慰剂组为18/421，4.3%）。在无基线止咳药使用的患者中（奥马珠单抗组n = 411，安慰剂组n = 403），大多数患者（奥马珠单抗组88.3%，安慰剂组83.4%）报告在48周治疗期内未使用止咳药。接受奥马珠单抗治疗的患者使用1种止咳药的百分比低于安慰剂组（7.1%对13.2%），尽管奥马珠单抗和安慰剂在治疗期间止咳药的调整使用率相似（分别为0.22和0.25）。非麻醉性止咳药的使用频率高于麻醉性止咳药。总之，该分析发现重度哮喘患者止咳药使用率较低，并表明奥马珠单抗可能有降低止咳药使用的潜力。
